文献速递新发突发、热带与寄生虫病

恶性疟原虫暴露与母体抗环子孢子蛋白抗体对婴幼儿和儿童接种RTS,S/AS01E疫苗应答的影响:一项3期随机临床试验的辅助观察性免疫学研究

The effect of Plasmodium falciparum exposure and maternal anti-circumsporozoite protein antibodies on responses to RTS,S/AS01E vaccination in infants and children: an ancillary observational immunological study to a phase 3, randomised clinical trial.
PubMed 文献 · Lancet Infect Dis · 2024-10-23

该辅助观察性免疫学研究纳入来自六个非洲国家的718名对照疫苗受种婴幼儿和儿童及606名RTS,S/AS01E受种者,评估既往恶性疟原虫暴露对疫苗抗体应答的影响及基线抗环子孢子蛋白(CSP)抗体的中介效应。儿童中既往暴露特征与抗CSP IgG应答无相关(Pearson r=-0.02),而婴儿中高暴露特征与疫苗应答降低相关(r=-0.17),抗CSP IgG的负相关更强(r=-0.42)。作者认为被动免疫与疫苗应答之间的干扰具有临床意义。

要点

  • 儿童中既往恶性疟原虫暴露特征与抗CSP IgG应答无显著相关(r=-0.02)。
  • 婴儿中高暴露特征与RTS,S/AS01E应答降低相关(r=-0.17)。
  • 婴儿中母体抗CSP IgG与疫苗应答负相关更强(r=-0.42)。

核心结论

  • 被动免疫与疫苗应答之间的干扰具有临床意义,可能影响针对小婴儿和母亲的新一代CSP基疫苗的实施以及人单克隆抗体被动免疫。

研究设计与样本

  • 本研究为RTS,S/AS01E 3期随机临床试验的MAL067免疫学辅助观察性研究。
  • 研究纳入来自布基纳法索、加蓬、加纳、肯尼亚、莫桑比克和坦桑尼亚六个非洲国家的婴幼儿和儿童,入组时间为2009年3月27日至2011年1月21日。
  • 纳入对照疫苗受种婴儿348例(48%)和儿童370例(52%),RTS,S/AS01E受种婴儿329例(54%)和儿童277例(46%)。
  • 使用部分蛋白质组微阵列检测针对1000种恶性疟原虫抗原的IgG水平,以鉴定既往暴露的抗体特征。
  • 通过ELISA测量疫苗抗体IgG应答,并与接种前疟疾暴露血清学标志物进行关联分析。

主要发现

  • 儿童中抗CSP IgG对初次接种的应答与既往暴露基线特征无相关(Pearson r=-0.02,95%CI -0.13至0.10)。
  • 婴儿中接种时高恶性疟原虫暴露特征水平与RTS,S/AS01E应答降低相关(r=-0.17,95%CI -0.27至-0.06)。
  • 婴儿中抗CSP IgG的负相关强于暴露特征或其他更具免疫原性的血液期恶性疟原虫抗原(r=-0.42,95%CI -0.50至-0.33)。
  • 调整暴露特征基线水平后负相关持续存在(半偏相关r=-0.44,95%CI -0.55至-0.33)。
  • 负相关涉及CSP中央NANP区抗体(r=-0.39,95%CI -0.49至-0.28),但不涉及C端区(r=0.02,95%CI -0.10至0.15)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The RTS,S/AS01E malaria vaccine showed lower antibody response and protective efficacy in infants aged 6-12 weeks compared with children aged 5-17 months (for whom this vaccine is recommended). We aimed to study the effect of previous Plasmodium falciparum exposure on the antibody responses to RTS,S/AS01E vaccination in infants and children, and the mediating effect of baseline (including maternal) anti-circumsporozoite protein (CSP) antibodies. METHODS: In this observational study, we included children and infants from six African countries (Burkina Faso, Gabon, Ghana, Kenya, Mozambique, and Tanzania) enrolled in the MAL067 immunology ancillary study of the RTS,S/AS01E phase 3 clinical trial from March 27, 2009, to Jan 21, 2011. We used comparator-vaccinated infants and children to identify antibody-based signatures of previous P falciparum exposure, which were later applied to RTS,S/AS01E-vaccinated infants and children. In these participants, we explored the relationship between vaccine antibody immunoglobulin G (IgG) responses measured by ELISA and pre-vaccination serological markers of malaria exposure by assessing the IgG levels against 1000 P falciparum antigens using partial proteome microarrays. FINDINGS: We included 718 comparator-vaccinated infants (348 [48%]) and children (370 [52%]) and 606 RTS,S/AS01E-vaccinated infants (329 [54%]) and children (277 [46%]). Anti-CSP IgG responses to primary vaccination did not correlate with a baseline signature of previous exposure in children, suggesting that prior P falciparum exposure does not significantly affect antibody immunogenicity in children (Pearson's r=-0·02 [95% CI -0·13 to 0·10]). By contrast, high P falciparum exposure signature levels at the time of vaccination in infants, presumably driven by maternally transferred antibodies and declining within the initial 6-12 months of life, correlated with reduced RTS,S/AS01E responses (r=-0·17 [-0·27 to -0·06]). This negative correlation was stronger for anti-CSP IgG than for the exposure signature or any other more immunogenic blood stage P falciparum antigens (r=-0·42 [-0·50 to -0·33]), persisted after adjustment by baseline levels of the exposure signature (semi-partial correlation r=-0·44 [-0·55 to -0·33]), and involved antibodies to the central NANP region (r=-0·39 [-0·49 to -0·28]) but not the C-terminal region (r=0·02 [-0·10 to 0·15]) of CSP. The negative effect of maternal anti-CSP IgG in infants did not appear to be confounded by other malaria transmission-dependent variables. INTERPRETATION: Interference between passive immunity and vaccine response is clinically significant and might affect the implementation of next-generation CSP-based vaccines for young infants and mothers as well as passive immunisation with human monoclonal antibodies. FUNDING: US National Institutes of Health, National Institute of Allergy and Infectious Diseases; PATH-Malaria Vaccine Initiative; Spanish Ministerio de Economía y Competitividad (Instituto de Salud Carlos III), European Regional Development Fund and European Social Fund; Fundación Ramón Areces; Spanish Ministry of Science and Innovation; and Generalitat de Catalunya (CERCA Program).

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Macià D, Campo JJ, Jairoce C, et al. The effect of Plasmodium falciparum exposure and maternal anti-circumsporozoite protein antibodies on responses to RTS,S/AS01E vaccination in infants and children: an ancillary observational immunological study to a phase 3, randomised clinical trial. Lancet Infect Dis. 2024. PMID: 39461358. doi:10.1016/S1473-3099(24)00527-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。